

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**SCHEDULE 13D**

Under the Securities Exchange Act of 1934  
(Amendment No. 3)

---

**Aimmune Therapeutics, Inc.**  
(Name of Issuer)

---

Common Stock, par value \$0.0001  
(Title of Class of Securities)

00900T107  
(CUSIP Number)

Nestlé S.A.  
Avenue Nestlé, 55  
1800 Vevey  
Switzerland

Attention: General Counsel  
Facsimile: 011-41-21-924-2821

with a copy to:

David A. Carpenter, Esq.  
Mayer Brown, LLP  
1221 Avenue of the Americas  
New York, New York 10020  
(212) 506-2195

(Name, Address and Telephone Number of Person Authorized to  
Receive Notices and Communications)

April 22, 2020  
(Date of Event which Requires Filing of this Statement)

---

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

---

**Note:** Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

---

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section of the Exchange Act but shall be subject to all other provisions of the Exchange Act (however, see the Notes).

---

---

1.	Name of Reporting Person Nestle Health Science US Holdings, Inc. (1)	
2.	Check the Appropriate Box if a Member of a Group (See Instructions)  (a) <input type="checkbox"/> (b) <input type="checkbox"/>	
3.	SEC Use Only:	
4.	Source of Funds (See Instructions):  WC	
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e):  <input type="checkbox"/>	
6.	Citizenship or Place of Organization:  Delaware	
Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power:  0
	8.	Shared Voting Power:  0
	9.	Sole Dispositive Power:  0
	10.	Shared Dispositive Power:  0
11.	Aggregate Amount Beneficially Owned by Each Reporting Person:  0	
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares: (See Instructions)  <input type="checkbox"/>	
13.	Percent of Class Represented by Amount in Row (11):  0%	
14.	Type of Reporting Person (See Instructions):  CO	

(1) Following the internal transfer referred to in Item 4 of this Schedule 13D, Nestle Health Science US Holdings, Inc. was removed from the beneficial ownership chain and will no longer be a Reporting Person.

1.	Name of Reporting Person NIMCO US, Inc. (1)	
2.	Check the Appropriate Box if a Member of a Group (See Instructions)  (a) <input type="checkbox"/> (b) <input type="checkbox"/>	
3.	SEC Use Only:	
4.	Source of Funds (See Instructions):  AF	
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e):  <input type="checkbox"/>	
6.	Citizenship or Place of Organization:  Delaware	
Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power:  0
	8.	Shared Voting Power:  0
	9.	Sole Dispositive Power:  0
	10.	Shared Dispositive Power:  0
11.	Aggregate Amount Beneficially Owned by Each Reporting Person:  0	
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares: (See Instructions)  <input type="checkbox"/>	
13.	Percent of Class Represented by Amount in Row (11):  0%	
14.	Type of Reporting Person (See Instructions):  CO	

(1) Following the internal transfer referred to in Item 4 of this Schedule 13D, NIMCO US, Inc. was removed from the beneficial ownership chain and will no longer be a Reporting Person.

1.	Name of Reporting Person Nestlé S.A.	
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) <input type="checkbox"/> (b) <input type="checkbox"/>	
3.	SEC Use Only:	
4.	Source of Funds (See Instructions): AF	
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e): <input type="checkbox"/>	
6.	Citizenship or Place of Organization: Switzerland	
Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power: 0
	8.	Shared Voting Power: 12,727,113
	9.	Sole Dispositive Power: 0
	10.	Shared Dispositive Power: 12,727,113
11.	Aggregate Amount Beneficially Owned by Each Reporting Person: 12,727,113	
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares: (See Instructions) <input type="checkbox"/>	
13.	Percent of Class Represented by Amount in Row (11): 19.6% (1)	
14.	Type of Reporting Person (See Instructions): CO	

(1) Based upon a total of 65,041,825 shares of Common Stock outstanding as of February 14, 2020, as reported by the Issuer in its Annual Report on Form 10-K for the year ending December 31, 2019, filed with the Securities and Exchange Commission on February 27, 2020.

1.	Name of Reporting Person Nestlé US Holdco, Inc. (1)	
2.	Check the Appropriate Box if a Member of a Group (See Instructions)  (a) <input type="checkbox"/> (b) <input type="checkbox"/>	
3.	SEC Use Only:	
4.	Source of Funds (See Instructions):  AF	
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e):  <input type="checkbox"/>	
6.	Citizenship or Place of Organization:  Delaware	
Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power:  0
	8.	Shared Voting Power:  0
	9.	Sole Dispositive Power:  0
	10.	Shared Dispositive Power:  0
11.	Aggregate Amount Beneficially Owned by Each Reporting Person:  0	
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares: (See Instructions)  <input type="checkbox"/>	
13.	Percent of Class Represented by Amount in Row (11):  0%	
14.	Type of Reporting Person (See Instructions):  CO	

(1) Following the internal transfer referred to in Item 4 of this Schedule 13D, Nestlé US Holdco, Inc. was removed from the beneficial ownership chain and will no longer be a Reporting Person.

1.	Name of Reporting Person <b>Société des Produits Nestlé S.A.</b>	
2.	Check the Appropriate Box if a Member of a Group (See Instructions)  (a) <input type="checkbox"/> (b) <input type="checkbox"/>	
3.	SEC Use Only:	
4.	Source of Funds (See Instructions):  AF	
5.	Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):  <input type="checkbox"/>	
6.	Citizenship or Place of Organization:  Switzerland	
Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power:  0
	8.	Shared Voting Power:  12,727,113
	9.	Sole Dispositive Power:  0
	10.	Shared Dispositive Power:  12,727,113
11.	Aggregate Amount Beneficially Owned by Each Reporting Person:  12,727,113	
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares: (See Instructions)  <input type="checkbox"/>	
13.	Percent of Class Represented by Amount in Row (11):  19.6% (1)	
14.	Type of Reporting Person (See Instructions):  CO	

(1) Based upon a total of 65,041,825 shares of Common Stock outstanding as of February 14, 2020, as reported by the Issuer in its Annual Report on Form 10-K for the year ending December 31, 2019, filed with the Securities and Exchange Commission on February 27, 2020.

**Explanatory Note**

Pursuant to Rule 13d-2 of the Securities Exchange Act of 1934, as amended, this Amendment No. 3 (this "Amendment") amends and supplements certain items of the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on March 5, 2018, as amended by Amendment No. 1 filed with the SEC on December 3, 2018, and as amended by Amendment No. 2 filed with the SEC on February 11, 2020 (together, the "Original Schedule 13D"), by the Reporting Persons relating to the Common Stock of Aimmune Therapeutics, Inc. (the "Issuer"). This Amendment amends the Original Schedule 13D on behalf of the Reporting Persons to furnish the information set forth herein. Except as set forth below, all Items of the Original Schedule 13D remain unchanged. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Original Schedule 13D.

**Item 4. Purpose of Transaction**

Item 4 of the Original Schedule 13D is hereby amended and supplemented to include the following:

On April 22, 2020, pursuant to an internal transfer, Nestle Health Science US Holdings, Inc. ("NHS") transferred to Société des Produits Nestlé S.A. ("SPN") 12,727,113 shares of common stock, par value \$0.0001 per share, and 525,634 shares of Series A Preferred Stock, par value \$0.0001 per share. In connection with the intercompany transfer, SPN assumed and agreed to perform and discharge all obligations and liabilities of NHS under the 2020 Purchase Agreement, 2020 Registration Rights Agreement, the 2020 Standstill Agreement, the November 2018 Purchase Agreement, and the 2016 Purchase Agreement. Following the internal transfer, NHS, NIMCO US, Inc. and Nestlé US Holdco, Inc., were removed from the beneficial ownership chain and will no longer be Reporting Persons.

The information in Item 6 of the Original Schedule 13D is incorporated by reference herein.

**Item 5. Interest in Securities of the Issuer**

The first paragraph of Item 5(a) – (b) of the Original Schedule 13D is hereby amended and restated as follows:

The information contained on the cover pages to this Amendment is incorporated herein by reference. The shares of Common Stock reported on this Amendment are directly held by SPN, which is a wholly-owned subsidiary of Nestlé S.A. Based upon information contained in its Annual Report on Form 10-K for the year ending December 31, 2019, filed with the SEC on February 27, 2020, the total issued and outstanding shares of Common Stock held by SPN comprises approximately 19.6% of the Issuer's issued and outstanding Common Stock.

Except for the shares of Common Stock and Series A Preferred Stock owned by SPN and the options held by Mr. Behar described in the Original Schedule 13D, none of the Reporting Persons or, to the knowledge of the Reporting Persons, any of the other persons listed on Schedule I hereto beneficially owns any other securities of the Issuer.

(c) Except as described in Item 3, neither the Reporting Persons nor, to the knowledge of the Reporting Persons, any person listed on Schedule I hereto, have effected any transactions in the Common Stock during the past 60 days.

(d) No other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities covered by this Amendment.

(e) Not applicable.

---

**Item 7. Material to be Filed as Exhibits**

Exhibit 1 Joint Filing Agreement (filed herewith).



**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated April 24, 2020

**NESTLE HEALTH SCIENCE US HOLDINGS, INC.**

By: /s/ James Pepin

Name: James Pepin

Title: Director and President

**NIMCO US, INC.**

By: /s/ Dan Nugent

Name: Dan Nugent

Title: Chief Legal Officer and General Counsel

**NESTLÉ S.A.**

By: /s/ Gregory Behar

Name: Gregory Behar

Title: Deputy Executive Vice President

**NESTLÉ US HOLDCO, INC.**

By: /s/ Michael Prewitt

Name: Michael Prewitt

Title: Secretary

**SOCIETE DES PRODUITS NESTLE S.A.**

By: /s/ Claudio Kuoni

Name: Claudio Kuoni

Title: Vice President

**DIRECTORS AND EXECUTIVE OFFICERS OF SPN,  
PERSONS CONTROLLING SPN AND EXECUTIVE OFFICERS AND DIRECTORS OF OTHER  
PERSONS IN CONTROL OF SPN**

**Société des Produits Nestlé S.A.**

Société des Produits Nestlé S.A. is organized under the laws of Switzerland with its principal business address at 55 Avenue Nestlé, CH-1800 Vevey Switzerland. Société des Produits Nestlé S.A. is a wholly-owned subsidiary of Nestlé. The name, present principal employment and citizenship of each director and executive officer of Société des Produits Nestlé S.A. is set forth below.

<u>Name</u>	<u>Present Principal Employment</u>	<u>Citizenship</u>
1. Stefan Helfenstein	Chairman of the Board, Société des Produits Nestlé S.A.	Swiss
2. Michèle Burger	Director, Société des Produits Nestlé S.A.	Swiss
3. José Checa Cortés	Director, Société des Produits Nestlé S.A.	Spanish
4. Thomas Hauser	Director, Société des Produits Nestlé S.A.	Swiss
5. Blaise Revillard	Director, Société des Produits Nestlé S.A.	French
6. Philippe Vossen	Director, Société des Produits Nestlé S.A.	Belgian
7. Silvan Jampen	Secretary (non Director), Société des Produits Nestlé S.A.	Swiss
8. Michel Gardet	Senior Vice President, Société des Produits Nestlé S.A.	French
9. Olivier Ballevre	Vice President, Société des Produits Nestlé S.A.	French
10. Trevor Douglas Brown	Vice President, Société des Produits Nestlé S.A.	Swiss
11. Harold Humbert	Vice President, Société des Produits Nestlé S.A.	French
12. Claudio Kuoni	Vice President, Société des Produits Nestlé S.A.	Swiss
13. Damien Tissot	Vice President, Société des Produits Nestlé S.A.	French

**Nestlé**

Nestlé is a corporation organized under the laws of Switzerland with its principal business address at Avenue Nestlé 55, CH-1800, Vevey Switzerland. The name, present principal employment and citizenship of each director and executive officer of Nestlé is set forth below.

<u>Name</u>	<u>Present Principal Employment</u>	<u>Citizenship</u>
1. Paul Bulcke	Non-Executive Director, Chairman, Nestlé S.A.; Vice-Chairman, L'Oréal S.A.; Board member, Roche Holding Ltd.	Belgian/Swiss
2. Ulf Mark Schneider	Chief Executive Officer, Board member, Nestlé S.A.	German/US

3.	Henri de Castris	Non-Executive Director; Vice Chairman, Lead Independent Director, Nestlé S.A.; Board member, HSBC Holdings plc, Argus Media	French
4.	Renato Fassbind	Non-Executive Director; Vice Chairman and Lead Independent Director, Swiss Re AG; Board member, Kühne+Nagel International AG	Swiss
5.	Ann M. Veneman	Non-Executive Director; Board member, the Global Health Innovative Technology Fund, Advisory Board member JUST Capital, the Clinton Health Access Initiative, the Full Harvest Technologies, Inc.	US
6.	Eva Cheng	Non-Executive Director; Board member, Trinity Limited, Haier Electronics Group Co. Ltd.	Chinese
7.	Patrick Aebischer	Non-Executive Director; President Emeritus of Institute EPFL, Professor of neurosciences at the Brain Mind Institute (EPFL); Board member: Logitech International S.A.; Chairman: Novartis Bioventures AG	Swiss
8.	Ursula M. Burns	Non-Executive Director; Chairman VEON Ltd.; Board member: Exxon Mobil Corporation, Ford Foundation, Uber Technologies	US
9.	Kasper Rorsted	Non-Executive Director; CEO, adidas AG	Danish
10.	Pablo Isla	Non-Executive Director; Chairman and CEO, Inditex S.A.	Spanish
11.	Kimberly A. Ross	Non-Executive Director; Board member: Chubb Ltd, PQ Corporation	US
12.	Dick Boer	Non-Executive Director; Chairman, Advisory Board of G-Star RAW CV, SHV Holdings N.V., Rijksmuseum Fonds	Netherlands
13.	Dinesh Paliwal	Non-Executive Director; Chairman and CEO, Harman International Industries Inc. Board member, Bristol-Myers Squibb, Raytheon Company, U.S.-India Business Council	US/Indian Overseas Citizenship
14.	Hanne Jimenez de Mora	Non-Executive Director; Board member: AB Volvo, Outotec Oyj; Vice-chair: IMD Business School	Swiss
15.	Laurent Freixe	Executive Vice President: Chief Executive Officer: Zone Americas	French
16.	Chris Johnson	Executive Vice President: Chief Executive Officer: Zone Asia, Oceania and sub-Saharan Africa	US

17. Patrice Bula	Executive Vice President: Strategic Business Units, Marketing, Sales and Nespresso; Board member: Novartis AG, Schindler Holding Ltd.	Swiss
18. Marco Settembri	Executive Vice President: Chief Executive Officer: Zone Europe, Middle East and North Africa	Italian
19. François-Xavier Roger	Executive Vice President: Chief Financial Officer (includes Finance and Control, Tax, Treasury, Investor Relations)	French
20. Magdi Batato	Executive Vice President: Head of Operations; Board member: Carlsberg A/S	Swiss
21. Stefan Palzer	Executive Vice President: Chief Technology Officer	German
22. Béatrice Guillaume-Grabisch	Executive Vice President: Global Head Human Resources & Business Services; Board member: L'Oréal S.A.	French
23. Leanne Geale	Executive Vice President: General Counsel, Corporate Governance and Compliance	Canada
24. Grégory Behar	Deputy Executive Vice President: Chief Executive Officer: Nestlé Health Science	Swiss
25. Sanjay Bahadur	Deputy Executive Vice President: Head of Group Strategy and Business Development	India
26. David P. Frick	Senior Vice President: Secretary to the Board of Directors: Head of Corporate Governance, Compliance and Corporate Services	Swiss

**JOINT FILING AGREEMENT**

The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of Société des Produits Nestlé S.A. and Nestlé S.A. who are the only remaining reporting persons following this statement on Schedule 13D. Société des Produits Nestlé S.A. and Nestlé S.A. acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

Dated April 24, 2020

**NESTLE HEALTH SCIENCE US HOLDINGS, INC.**

By: /s/ James Pepin

Name: James Pepin

Title: Director and President

**NIMCO US, INC.**

By: /s/ Dan Nugent

Name: Dan Nugent

Title: Chief Legal Officer and General Counsel

**NESTLÉ S.A.**

By: /s/ Gregory Behar

Name: Gregory Behar

Title: Deputy Executive Vice President

**NESTLÉ US HOLDCO, INC.**

By: /s/ Michael Prewitt

Name: Michael Prewitt

Title: Secretary

**SOCIETE DES PRODUITS NESTLE S.A.**

By: /s/ Claudio Kuoni

Name: Claudio Kuoni

Title: Vice President